Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04684147 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv7
  2. Study completion date: Mar 2024 to Dec 31, 2026v6
  3. Study sites: 9 to 11
    • Eligibility criteria shortened, about 40 words
    v5
  4. Primary completion date changed from estimate of Jul 30, 2022 to Sep 22, 2022v4
  5. Primary completion date: Dec 2021 to Jul 30, 2022v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Aug 2021 to Dec 2021
    • Start date changed from estimate of Dec 2020 to Dec 24, 2020
    • Site details revised at 9 of 9 sites
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.
Trial Details
NCT Number NCT04684147
Lead Sponsor Juventas Cell Therapy Ltd.
Conditions
(from sponsor)		 Relapsed or Refractory Acute Lymphoblastic Leukemia
Related terms Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov